Compare Sanofi SA (SNY) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.74 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is the larger of the two by market cap, and Sanofi SA pays a 6.01% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| SNY | VWO | |
|---|---|---|
Market Cap | $95.18B | $168.50B |
Volume | 2,995,646 | 9,650,999 |
Sector | Health | — |
52-Week High | $52.34 | $61.44 |
52-Week Low | $39.51 | $52.42 |
Typical Hold Time | 94 Days | 135 Days |
Enterprise Value | $114.48B | — |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
VWO trades at $59.67, down 0.3% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic slowdown weighs on performance. Recent news highlights institutional accumulation with Allianz and Alamar Capital increasing positions, though comparisons show developed market ETFs like VEA offer lower expense ratios and higher yields.
Outlook remains cautious with technical resistance at $60 and support at $59. Emerging markets face headwinds from China's weak retail and property sectors, though AI infrastructure spending offers partial offset. Investors should monitor dollar weakness as a potential catalyst for EM equities while weighing concentration risks in single-country exposures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
